Medimmune
  • ABOUT MEDIMMUNE
    • Key Facts & Figures
    • Products
    • Facilities
    • At the Forefront
  • OUR CULTURE
    • History & Highlights
    • Visionaries at MedImmune
    • Executive Team
    • Corporate Responsibility
  • R & D
    • Pipeline
    • Drug Phase Chart
    • Biologics
    • Technologies & Approaches
    • Partnering
  • VENTURES
  • PRESS ROOM
  • CAREERS
  • CONTACT
  • Home >
    • News & Media

News and Media

For press releases:

2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999

Receive E-mail alerts

Subscribe to RSS feeds

December 7, 2004
MedImmune's Chief Financial Officer Named a 'Woman Who Means Business' by Washington Business Journal
November 23, 2004
MedImmune and Medarex Announce Collaboration to Develop and Commercialize Fully Human Antibodies for Autoimmune Diseases
November 15, 2004
MedImmune Initiates Phase 3 Study for Numax(TM) in Native American Infants
November 15, 2004
MedImmune Appoints New Vice President, Medical Affairs
November 1, 2004
MedImmune Initiates Pivotal Phase 3 Study for Numax(TM) to Prevent Respiratory Syncytial Virus in High-Risk Infants
November 1, 2004
MedImmune Completes Enrollment in Phase 3 Study Comparing Next-Generation, Intranasal Influenza Vaccine to Injectable Influenza Vaccine
October 28, 2004
CDC Advisory Committee Votes to Include FluMist(R) in the Vaccines for Children Program for 2005-2006 Influenza Season
October 21, 2004
MedImmune Expands Production Plans For FluMist(R)
October 21, 2004
MedImmune Reports Record Revenues for First Nine Months of 2004
October 20, 2004
MedImmune Initiates Phase 3 Clinical Trial Comparing Intranasal Influenza Vaccine With Injectable Flu Vaccine
October 19, 2004
MedImmune Promotes Edward Connor, M.D., to Executive Vice President & Chief Medical Officer and Appoints New Senior Executives
October 13, 2004
MedImmune Progressing with Development of Vaccine Targeting Respiratory Syncytial Virus and Parainfluenza Virus Type-3
October 11, 2004
MedImmune Named One of Maryland's Fastest Growing Technology Companies in Deloitte Technology Fast 50 Program
October 7, 2004
FluMist(R) Now Available for the 2004-2005 Flu Season
September 30, 2004
MedImmune and GenPat77 Sign License and Collaboration Agreement on Novel Therapeutic Target
September 21, 2004
MedImmune to Announce 2004 Third Quarter Financial Results on October 21, 2004
August 30, 2004
MedImmune Discontinues Rheumatoid Arthritis and Psoriasis Trials for Vitaxin(R)
August 18, 2004
MedImmune Begins Phase 1 Clinical Trial for Its Anti-Interleukin-9 Monoclonal Antibody
August 11, 2004
MedImmune's Newly Identified EphA2 Protein May Signal Progression of Ovarian Cancer
July 26, 2004
FDA Approves Liquid Formulation of Synagis(R)
July 22, 2004
MedImmune Reports 2004 Second Quarter and Six-Month Results
July 1, 2004
MedImmune to Announce 2004 Second Quarter Financial Results on July 22, 2004
June 23, 2004
MedImmune's New R&D Facility and Corporate Headquarters Named 'Best Biotech Office'
June 15, 2004
MedImmune Selects Henry Schein as Exclusive Distributor of FluMist(TM)
June 6, 2004
Data Show Ethyol(R) Reduces Radiation Therapy-Induced Dry Mouth in Head and Neck Cancer Patients For 24 Months
May 21, 2004
FTC Clears MedImmune Reacquisition of Intranasal Influenza Vaccine Products
May 20, 2004
MedImmune Provides Update to Investors at 2004 Annual Shareholders' Meeting
May 3, 2004
Intranasal Influenza Vaccine Shows Higher Efficacy Rate Compared to Traditional Flu Shot
April 27, 2004
MedImmune Incorporates Reacquisition of FluMist(TM) Franchise from Wyeth into Financial Guidance
April 26, 2004
MedImmune Reacquires Rights to Intranasal Influenza Vaccine Products from Wyeth
April 26, 2004
MedImmune to Provide Strategic Update for Investors on April 27, 2004
April 21, 2004
MedImmune Reports Record Revenues and Earnings for First Quarter 2004
April 21, 2004
MedImmune Appoints CFO, Promotes Several Senior Executives
April 21, 2004
MedImmune and Cerus Enter Agreement to Co-Develop Therapeutic Vaccine For Cancer
April 7, 2004
MedImmune to Announce First Quarter 2004 Financial Results on April 21, 2004
March 29, 2004
MedImmune and Cerus to Present Data on Novel Vaccine Technology's Potential to Help Treat and Prevent Cancers
March 1, 2004
MedImmune Implements Plan to Achieve $2 Billion In Revenues By 2009
February 23, 2004
MedImmune to Provide 2004 and Long-Term Financial Guidance on March 1, 2004
February 23, 2004
MedImmune Identifies Novel Protein Target for Cancer Therapy
January 29, 2004
MedImmune Reports Record Revenues and Earnings for 2003
January 23, 2004
MedImmune to Provide Financial Guidance for 2004 on March 1, 2004
January 15, 2004
MedImmune to Announce 2003 Fourth Quarter and Year End Financial Results on January 29, 2004
January 8, 2004
MedImmune Announces Departure of Chief Financial Officer
  • Terms and Conditions
  • |
  • Privacy Policy
  • |
  • Site Map
  • |
  • Contact Us
  • |
  • Glossary
Copyright © 2011 MedImmune, LLC. All rights reserved.